San Diego has a rich biotech ecosystem. From startups and small to mid-cap companies to major and well-established players. According to Connect (San Diego), there were 65 life sciences venture-funded deals in 2023 (Figure 1). đ¸
Below are some promising biopharma companies to keep an eye on in sunny SD âď¸
Replay
Overview: The company is a genome writing company that develops innovative technologies to revolutionize genomic medicine, and launches subsidiaries that develop those therapies. Their platforms enable the delivery of large DNA payloads and optimize enzyme functionality, with applications in gene therapy for various diseases and enhanced enzyme production.
Ownership:Â Private
Pipeline/Funding OverviewÂ
Disclosed Programs:Â 4 drugs/therapies
Technologies: TCR NK-Cell Therapy & Gene Therapy
Furthest Asset & Stage Development: SY-104 (Phase 1)
Disease Areas:Â Oncology, Rare Diseases, Genetic Diseases
Latest Funding News:Â 7/25/22 $55M seed funding from KKR and OMX Ventures.Â
Cessation Therapeutics, Inc.
Overview:Â The company is developing novel antibody therapies to prevent and reverse overdose related to fentanyl and fentanyl analogs
Ownership:Â Private
Pipeline/Funding OverviewÂ
Disclosed Programs:Â 3 drugs/therapies
Technologies: Monoclonal Antibody (mAb) Cell Therapy
Furthest Asset & Stage Development: CSX-1004 (Phase 1)
Disease Areas:Â Fentanyl, opioid, smoking, cannabis addiction
Latest Funding News:Â 10/18/23 $14.8M grant from NIH-NIDA to support the development of the subcutaneous formulation of its anti-fentanyl mAb, CSX-1004 SQ.Â
SelectION
Overview: A clinical-stage biopharmaceutical company specializing in peptide therapies for autoimmune diseases and certain cancers. Their unique technology platform allows them to develop highly targeted drugs with improved safety and efficacy compared to existing treatments.
Ownership:Â Private
Pipeline/Funding OverviewÂ
Disclosed Programs:Â 2 drugs/therapies
Technologies: Peptides
Furthest Asset & Stage Development: si-544 (Phase 1b)
Disease Areas:Â Autoimmune diseases and Cancer
Latest Funding News: 9/16/20 $5M convertible promissory note financing in 2020 to advance si-544 into clinical development in early 2021. Â
Revelation Biosciences Inc.
Overview: A life sciences company developing immune system therapies, using their Gemini formulation, to prevent and treat diseases like post-surgical infections, acute kidney injury, and chronic kidney disease.
Ownership:Â Public (NASDAQ: REVB)
Pipeline/Funding OverviewÂ
Disclosed Programs:Â 1 drug/therapy
Technologies: Small molecule
Furthest Asset & Stage Development: Gemini (Phase 1)
Disease Areas:Â Infectious diseases and Kidney diseases
Latest Funding News: 2/5/24 Closed $6.2M public offering. Proceeds will be used to advance Gemini-based drug pipeline assets. Â
Tempo Therapeutics
Overview: A privately held clinical-stage company specializing in tissue engineering. They develop innovative synthetic biomaterials, using their patented MAP technology, for surgical reconstruction and various regenerative medicine applications.
Ownership:Â Private
Pipeline/Funding OverviewÂ
Disclosed Programs:Â 4 drugs/therapies
Technologies: Medical device [synthetic material (hydrogel polymer-based components)]
Furthest Asset & Stage Development: TT101Â
Disease Areas:Â Oncology, Regenerative Medicine
Latest Funding News:Â 3/19/24 Completed $12M Series A equity financing round led by Galaxy-Sirius Partners and Johnson & Johnson Innovation â JJDC, Inc. (JJDC). The funding will be used to advance the companyâs Microporous Annealed Particle (MAP) technology platform and take its synthetic tissue scaffold candidates into clinical trials.
![](https://static.wixstatic.com/media/5decac_6c606b88fa0d4368a80b6cc88fff82a1~mv2.gif)
Figure 1. San Diego Biotech Sector 2024.
---
Get a list of all recently funded companies with deeper info to help your sales/BD activities. Contact us to learn more
Article History:
RF, DV, EV (04/20/24)
This article is not investment or legal advice.
Comments